Form 4: Foghorn Therapeutics Executive Carlos Costa Executes Option and Sells Shares Under 10b5-1 Plan

Carlos Costa, Chief People Officer of Foghorn Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carlos Costa, the Chief People Officer of Foghorn Therapeutics, executed a transaction involving the company's stock on September 18, 2024.
• Costa exercised stock options to acquire 11,574 shares of common stock at a price of $3.72 per share.
• Simultaneously, Costa sold 11,574 shares of common stock at a weighted average price of $10.05 per share, with individual transactions ranging from $10.00 to $10.25.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2024.
• Following these transactions, Costa directly holds 76,402 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and their potential alignment with shareholder interests. The use of a 10b5-1 plan suggests a pre-planned and systematic approach to these transactions.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company executives as an indicator of management's confidence in the company's prospects.

Key Dates